[HTML][HTML] International experts consensus guidelines on robotic liver resection in 2023

R Liu, MA Hilal, G Wakabayashi, HS Han… - World Journal of …, 2023 - ncbi.nlm.nih.gov
The robotic liver resection (RLR) has been increasingly applied in recent years and its
benefits shown in some aspects owing to the technical advancement of robotic surgical …

[HTML][HTML] Exploring the JAK/STAT signaling pathway in hepatocellular carcinoma: unraveling signaling complexity and therapeutic implications

H Park, S Lee, J Lee, H Moon, SW Ro - International Journal of Molecular …, 2023 - mdpi.com
Hepatocellular Carcinoma (HCC) continues to pose a substantial global health challenge
due to its high incidence and limited therapeutic options. In recent years, the Janus Kinase …

A phase I/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma

YB Lee, JY Nam, EJ Cho, JH Lee, SJ Yu, HC Kim… - Clinical Cancer …, 2023 - AACR
Purpose: Synergistic effect of radiotherapy and immunotherapy for the treatment of
hepatocellular carcinoma (HCC) has been reported. This phase I/IIa pilot trial evaluated …

A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for …

Z Tian, Q Hu, Z Sun, N Wang, H He, Z Tang, W Chen - Acs Nano, 2023 - ACS Publications
Radiofrequency ablation (RFA) is one of the most common minimally invasive techniques for
treating hepatocellular carcinoma (HCC), which could destroy tumors through hyperthermia …

[HTML][HTML] The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy?

SP Papadakos, D Ferraro, G Carbone, AE Frampton… - Cancers, 2023 - mdpi.com
Simple Summary The study investigates the potential use of metformin, a medication
commonly prescribed for type 2 diabetes, in the treatment of hepatocellular carcinoma …

[HTML][HTML] Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

SP Papadakos, IE Stergiou, N Gkolemi, K Arvanitakis… - Cancers, 2023 - mdpi.com
Simple Summary This narrative literature review delves into the role of EPH/ephrin signaling
in liver cancer and its implications for tumor progression and potential therapeutic strategies …

The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy

J Ouyang, Y Yang, Y Zhou, F Ye, Z Wang, Q Li… - Hepatology …, 2023 - Springer
Abstract Background Body composition parameters (BCPs) are associated with mortality in
patients with hepatocellular carcinoma (HCC). Our purpose was to develop a practical …

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations

M Zhao, Z Guo, YH Zou, X Li, ZP Yan, MS Chen… - Hepatology …, 2024 - Springer
Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third
leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy …

Real-world use of immunotherapy for hepatocellular carcinoma

A Sara, SM Ruff, AM Noonan… - Pragmatic and …, 2023 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality
worldwide and accounts for 90% of all primary liver cancers. Chronic inflammation is the …

A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: the LAUNCH study

K Kobayashi, S Ogasawara, S Maruta, T Okubo… - Clinical Cancer …, 2023 - AACR
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world
settings, including patients excluded from the REFLECT trial, a phase III trial that compared …